Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease (Q48880365)

16 February 2018

title

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease (English)

1 reference

16 February 2018

1 reference

1 reference

1 reference

3

1 reference

16 February 2018

Rivka Inzelberg

object named as

Rivka Inzelberg

5

0 references

Yael Laitman

9

object named as

Yael Laitman

1 reference

16 February 2018

Saharon Rosset

11

object named as

Saharon Rosset

1 reference

16 February 2018

author name string

Natalie Kaplan

1

1 reference

16 February 2018

Aya Vituri

2

1 reference

16 February 2018

Oren S Cohen

4

1 reference

16 February 2018

Gilad Yahalom

6

1 reference

16 February 2018

Evgenia Kozlova

7

1 reference

16 February 2018

Roni Milgrom

8

1 reference

16 February 2018

Eitan Friedman

10

1 reference

16 February 2018

Sharon Hassin-Baer

12

1 reference

16 February 2018

publication date

15 March 2014

1 reference

16 February 2018

Journal of Molecular Neuroscience

published in

1 reference

16 February 2018

volume

53

1 reference

16 February 2018

issue

2

1 reference

16 February 2018

page(s)

183-188

1 reference

16 February 2018

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Listening to silence and understanding nonsense: exonic mutations that affect splicing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Dopamine transporter genotype predicts behavioural and neural measures of response inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Gender effect on time to levodopa-induced dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Touchdown PCR for increased specificity and sensitivity in PCR amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Differential genetic susceptibility in diphasic and peak-dose dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Motor fluctuations and dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Fine-mapping reveals novel alternative splicing of the dopamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Dopamine transporter: Basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12031-014-0276-9

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease

21 January 2018

1 reference

12 December 2020

Genetic polymorphisms in the DRD2, DRD3, and SLC6A3 gene in elderly patients with delirium

1 reference

12 December 2020

The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease

1 reference

12 December 2020

The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis

1 reference

12 December 2020

L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects

1 reference

12 December 2020

Is there a need to redefine Parkinson's disease?

1 reference

12 December 2020

10.1007/S12031-014-0276-9

Identifiers

DOI

1 reference

16 February 2018

1 reference

16 February 2018